October 8, 2009 (FinancialWire) — Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), an innovative cancer drug discovery and development company, announced that Thomas J. Lynch, Jr., M.D., has been appointed to its board of directors.

Dr. Lynch is the director of the Yale Cancer Center and the Physician-in-Chief at Smilow Cancer Hospital at Yale-New Haven. He has focused his career on the care and treatment of patients with lung cancer and the clinical development of novel agents targeting lung cancer. Recently, his work has focused on agents directed against the epidermal growth factor receptor  and the potential role that EGFR mutations play in lung cancer biology. Prior to 2009, Dr. Lynch was the Chief of Hematology-Oncology at Massachusetts General Hospital  and a Professor of Medicine at Harvard Medical School. He received his M.D. from Yale University and completed his internship and residency at MGH. Before joining the staff at MGH, Dr. Lynch served as a fellow in medical oncology at the Dana-Farber Cancer Institute. Dr. Lynch is a founding board member and vice chair of the board of the Kenneth B. Schwartz Center, a foundation devoted to promoting compassionate health care.

“Infinity is delighted to welcome Dr. Lynch to our board of directors,” said Steven H. Holtzman, chair and chief executive officer, Infinity. “Dr. Lynch’s professional reputation, extensive experience in clinical oncology, particularly in lung cancer, and passion for patients position him to be a valuable asset to, and have an immediate impact on, our organization.”

“I am pleased to be joining Infinity’s board of directors,” said Dr. Lynch. “I look forward to being part of Infinity’s current and future efforts to successfully develop novel treatments for patients with cancer.”

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.